CVS Health (NYSE:CVS) announced on Tuesday its optimistic projection for 2024 revenue, surpassing market expectations. The company also revealed plans to streamline the process through which its pharmacies are reimbursed for drugs, introducing a new model named CostVantage, aimed at enhancing transparency in response to the increasing scrutiny on rising healthcare costs.
Under the CostVantage model, CVS’s extensive network of over 9,000 pharmacies will implement a fixed markup and fee structure to define drug costs and associated reimbursements with contracted insurers and pharmacy benefit managers (PBMs). This departure from the current convoluted system, involving insurers, drugmakers, pharmacies, and PBMs in determining out-of-pocket drug prices, aims to eliminate ambiguity surrounding fees and markups.
During the company’s investor day, CVS CEO Karen Lynch emphasized the necessity for change, driven by consumer and government demands for transparency. The new model is set to be rolled out for commercial insurance plans starting in 2025, with expectations of benefiting the pharmacy and consumer wellness unit.
In response to these developments, CVS shares experienced a 4% rise in afternoon trade, reflecting investor confidence in the company’s strategic initiatives. Lynch expressed confidence in CVS’s long-term earnings growth, projecting at least 6%, with a recovery in margins from its Medicare Advantage plans anticipated in 2025, contributing to a potential 9% to 10% rise in adjusted earnings per share for the year.
The company’s 2024 revenue outlook is robust, with expectations set at a minimum of $366 billion, exceeding estimates by LSEG, which projected $345.81 billion.
Additionally, CVS outlined plans for its pharmacy benefit manager (PBM) unit, Caremark, to launch a program called TrueCost in 2025. TrueCost aims to provide clients with increased visibility into prescription drug pricing and administrative fees, addressing the growing concerns and political scrutiny faced by PBMs for their role in escalating drug costs.
While CVS’s initiatives toward transparency were well-received, shares of GoodRx (NASDAQ:GDRX), a provider of prescription drug discount coupons, faced a nearly 10% slump as CVS’s new program raised competitive concerns. Industry experts view CVS’s move as a positive step toward transparency in the drug supply chain but emphasize the need for continued efforts to ensure transparency across all aspects of drug pricing and distribution.
Featured Image: Unsplash
